MedTrace Logo

The Efficacy and Safety of Sirolimus for Plastic Bronchitis

NCT03942926 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-05-10

No results posted yet for this study

Summary

There is no confirmed drug therapy for plastic bronchitis. The study wish to test the effectiveness and safety of sirolimus (rapamycin) in patients with lymphatic plastic bronchitis.

Conditions

  • Plastic Bronchitis

Interventions

DRUG

Sirolimus

Patients will receive sirolimus for 6 months.

Sponsors & Collaborators

  • North-China Pharmaceutical Company, China

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Kai-Feng Xu, MD · Peking Union Medical College Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-06
Primary Completion
2020-05-05
Completion
2020-05-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03942926 on ClinicalTrials.gov